Session

Pharmaceutical and Natural Sciences

Description

Acute lymphoblastic leukemia (ALL) is known as a heterogeneous disease. The progress is possible to make in understanding of biological mechanism who play pivotal role in the development of therapies. Here I will try to summarize the current and future possibilities of management of adult and children ALL. Many inhibitors are used to inhibit tyrosine kinase, chimeric antigen receptor and gene therapy for cure of ALL. The FDA has approved a number of drugs for treatment of children who are sick from ALL. Currently, is known that long term of survival is achieved in more than 50% of patients with B-ALL, 50-60% T-ALL, and 80% mature ALL. In era of precision medicine, the future is based in using of less cytotoxic and based and more target agents.

Keywords:

acute lymphoblastic leukemia, clinical features, chemotherapy, immunotherapy

Proceedings Editor

Edmond Hajrizi

ISBN

978-9951-550-47-5

First Page

1

Last Page

6

Location

UBT Kampus, Lipjan

Start Date

30-10-2021 12:00 AM

End Date

30-10-2021 12:00 AM

DOI

10.33107/ubt-ic.2021.97

Download

Share

COinS
 
Oct 30th, 12:00 AM Oct 30th, 12:00 AM

Immunotherapy in Childhood Acute Lymphoblastic Leukemia

UBT Kampus, Lipjan

Acute lymphoblastic leukemia (ALL) is known as a heterogeneous disease. The progress is possible to make in understanding of biological mechanism who play pivotal role in the development of therapies. Here I will try to summarize the current and future possibilities of management of adult and children ALL. Many inhibitors are used to inhibit tyrosine kinase, chimeric antigen receptor and gene therapy for cure of ALL. The FDA has approved a number of drugs for treatment of children who are sick from ALL. Currently, is known that long term of survival is achieved in more than 50% of patients with B-ALL, 50-60% T-ALL, and 80% mature ALL. In era of precision medicine, the future is based in using of less cytotoxic and based and more target agents.